Enzyme-linked immunosorbent assay (ELISA) is an analytic biochemical assay that utilizes enzyme-linked antibodies on a microwell platform to quantitate specific proteins within biological samples. Visual detection is then achieved by adding the enzyme’s substrate, which causes a color-changing reaction to occur. There are three different types of ELISA that are most commonly used: indirect ELISA, sandwich ELISA and competitive ELISA. These assays are extremely useful for high-throughput diagnostic screenings drug testing.
Novus offers a range of support options for ELISA when you buy a product to help you with your ELISA experiment including:
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77299SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-13075SS | |||
| Azide and BSA Free | NBP2-80594 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | PDVR100C | |||
| Carrier Free | SVR100C | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | PDET100 | |||
| Carrier Free | SET100 | |||
![N/A IL-17/IL-17A [HRP]](http://images.novusbio.com/fullsize2/DATA_IL17_D1700_ELISA_539.jpg "N/A IL-17/IL-17A [HRP]")
![N/A IL-17/IL-17A [HRP]](http://images.novusbio.com/fullsize2/DATA_IL17_D1700_ELISA_540.jpg)
![N/A IL-17/IL-17A [HRP]](http://images.novusbio.com/fullsize2/IL-17_D1700_ELISA_15.jpg)
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Analysis of RIP3 in HeLa cell lysate with RIPK3/RIP3 antibody [NBP1-77299] at (A) 1 and (B) 2 ug/mL. Observed molecular weight ~60 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0014.jpg "Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Analysis of RIP3 in HeLa cell lysate with RIPK3/RIP3 antibody [NBP1-77299] at (A) 1 and (B) 2 ug/mL. Observed molecular weight ~60 kDa. Theoretical molecular weight 53 kDa.")
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Mouse Cell lines. 15 ug of lysates per lane. Antibodies: [NBP1-77299], (0.5 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Observed molecular weight ~50 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0022.jpg)
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Analysis using RIPK3/RIP3 antibody [NBP1-77299]. L929 cell line (mouse). 20 ug whole cell lysate. Primary antibody: 1:2000. Secondary antibody: 1:20000. Western blot image submitted by a verified customer review. Observed molecular weight ~57 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0024.jpg)
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - C2C12 Cells. 15 ug of lysates per lane. Antibodies: RIPK3/RIP3 antibody [NBP1-77299], 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: NBP1-77299, 0.1 ug/mL in the presence of peptide blocking. Lane 2: NBP1-77299, 0.1 ug/mL Lane 3: NBP1-77299, 0.2 ug/mL Lane 4: NBP1-77299, 0.5 ug/mL. Observed molecular weight ~55 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0021.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Bone-marrow-derived macrophages exhibit significant reduction in RIPK3/RIP3 levels in RIPK3/RIP3deltaGlobal, RIPK3/RIP3deltaMphi-Cre and RIPK3/RIP3deltaEC-Cre mice. Protein lysates were immunoblotted to identify CD11b, RIPK3/RIP3 and beta-actin (loading control). Image collected and cropped by CiteAb from the following publication (www.dmm.biologists.org/lookup/doi/10.1242/dmm.041962) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Knockout-Validated-NBP1-77299-img0025.jpg)
![<b>Genetic Strategies Validation. </b>Knockdown Validated: RIPK3/RIP3 Antibody [NBP1-77299] - RIPK3/RIP3-deficiency impacts MCP-1 and IL-1beta expression in BMDMs and MCP-1 and E-Selectin/CD62E expression in cultured endothelial cells. Protein lysates were immunoblotted for RIPK3/RIP3 and the loading control, GAPDH (n=4 independent experiments). Image collected and cropped by CiteAb from the following publication (www.dmm.biologists.org/content/13/1/dmm041962) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Knockdown-Validated-NBP1-77299-img0026.jpg)
![Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP1-77299] - Bone-marrow-derived macrophages exhibit significant reduction in RIPK3 levels in Ripk3 delta Global, Ripk3 delta MΦ-Cre & Ripk3 delta EC-Cre mice. (A,B) BMDMs were isolated, differentiated on chamber slides for 7 days, immunostained for macrophage markers CD68 (red; A) & CD11b (pink; B), & co-stained for nuclei (Hoechst; blue). All cells from seven separate BMDM isolations were positive for these markers (n=7). (C) A phagocytosis assay was performed on BMDMs with fluorescent polystyrene beads. Phagocytic cells display TRITC+/Hoechst+ signal, & 85% of cells from two separate BMDM isolations were double positive (n=2). (D-F) Protein or RNA was collected from control, Ripk3 delta Global, Ripk3 delta MΦ-Cre & Ripk3 delta EC-Cre BMDMs. RNA was converted to cDNA & analyzed by qPCR for Ripk3 levels (D). Protein lysates were immunoblotted to identify CD11b, RIPK3 & beta -actin (loading control) (E) & quantified (F). (G) RNA from control & Ripk3 delta Global BMDMs was converted to cDNA & analyzed by qPCR for Ripk3-Exon 10 levels. For panels D,F,G, each dot represents a BMDM isolation from an individual animal. Statistics for panels D & F were calculated using one-way ANOVA with Dunnett's multiple comparisons test. Overall ANOVA P-values (prior to the post hoc tests) are 0.0002 (D) & <0.0001 (F). Statistics for panel G were calculated using an unpaired t-test with Welch's correction. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Data are mean±s.d. Scale bars: 25 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31953345), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77299_rabbit-polyclonal-ripk3-rip3-antibody-310202416171485.jpg)
![Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP1-77299] - p-MLKL levels are nearly undetectable in advanced plaques. (A-C) After 3 months on a Western diet, protein was collected from control (n=7), Ripk3 delta MΦ-Cre (n=5), Ripk3 delta EC-Cre (n=3) & Ripk3 delta SMC-Cre (n=3) aortas. Protein lysates were immunoblotted to identify p-MLKL (Abcam; #ab196436), MLKL & beta -actin (loading control) (A) & quantified (B,C). A faint positive p-MLKL signal can be seen in the representative blot in the control arch region; however, we could only detect p-MLKL in two out of the 18 aortas analyzed (B). Note that the same transfer membrane used for detecting CD11b (in Fig. 4S) was reprobed for p-MLKL & MLKL in A; the beta -actin control blots are therefore the same in both figures. (D,E) Protein lysates were immunoblotted to identify RIPK3 & GAPDH (loading control) (D) & quantified (E). For panels B,C,E, each dot represents an individual animal. Statistics were calculated using two-way ANOVA. Overall ANOVA P-values are 0.76 (B), 0.07 (C) & 0.46 (E). Data are mean±s.d. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31953345), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77299_rabbit-polyclonal-ripk3-rip3-antibody-31020241616072.jpg)
![Immunocytochemistry/ Immunofluorescence: RIPK3/RIP3 Antibody - BSA Free [NBP1-77299] - Validation of RIPK3/RIP3 in Rat Kidney Tissue. Immunofluorescent analysis of 4% paraformaldehyde-fixed Rat Kidney tissue labeling RIPK3/RIP3 with at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).](http://images.novusbio.com/fullsize/nbp1-77299_rabbit-polyclonal-ripk3-rip3-antibody-2711202419562182.jpg)
![Immunohistochemistry: RIPK3/RIP3 Antibody - BSA Free [NBP1-77299] - Validation of RIPK3/RIP3 in Mouse Kidney Tissue. Immunohistochemical analysis of paraffin-embedded mouse kidney tissue using anti-RIPK3/RIP3 antibody at 2.5 ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/nbp1-77299_rabbit-polyclonal-ripk3-rip3-antibody-2711202419333448.gif)
![Immunohistochemistry: RIPK3/RIP3 Antibody - BSA Free [NBP1-77299] - Validation of RIPK3/RIP3 in Rat Kidney Tissue.Immunohistochemical analysis of paraffin-embedded rat kidney tissue using anti-RIPK3/RIP3 antibody at 5 ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/nbp1-77299_rabbit-polyclonal-ripk3-rip3-antibody-271120242074698.jpg)
![Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP1-77299] - Validation in Human Cell Lines. Loading: 15 ug of lysates per lane.Antibodies: RIPK3/RIP3 , (0.5 ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/nbp1-77299_rabbit-polyclonal-ripk3-rip3-antibody-2711202420243399.gif)
![N/A IL-2 [HRP]](http://images.novusbio.com/fullsize2/d2050_human-il-2-quantikine-sixpak-6-plates-293202165324.jpg "N/A IL-2 [HRP]")
![N/A IL-2 [HRP]](http://images.novusbio.com/fullsize2/d2050_human-il-2-quantikine-sixpak-6-plates-293202165420.jpg)
![N/A IL-2 [HRP]](http://images.novusbio.com/fullsize2/d2050_human-il-2-quantikine-sixpak-6-plates-29320216567.jpg)
![N/A IL-5 [HRP]](http://images.novusbio.com/fullsize2/DATA_IL5_M5000_ELISA_935.jpg "N/A IL-5 [HRP]")
![N/A IL-5 [HRP]](http://images.novusbio.com/fullsize2/IL-5_M5000_ELISA_237.jpg)
![N/A Osteoprotegerin/TNFRSF11B [Biotin]](http://images.novusbio.com/fullsize2/DATA_Osteoprotegerin_DY805_ELISA_2238.jpg "N/A Osteoprotegerin/TNFRSF11B [Biotin]")
![Immunocytochemistry/ Immunofluorescence: beta Amyloid Antibody (MOAB-2) - BSA Free [NBP2-13075] - No difference in A beta plaque load between propofol (n = 8) & vehicle (n = 6) treated APP/PS1 mice. a An example image of A beta plaque immunoreactivity in the cortex of an APP/PS1 mouse following repeated propofol exposure. b A representative image of A beta plaque immunolabeling the cortex of an APP/PS1 mouse following treatment with vehicle. c Bar graph showing the percentage of the cortex occupied by A beta plaques in propofol & vehicle treated APP/PS1 mice. d Bar graph showing the average size (μm2) of A beta plaques in the cortex of APP/PS1 in the propofol & vehicle treatment groups. e Bar graph showing the average density of A beta plaques (/μm2) in the cortex of propofol & vehicle exposed APP/PS1 mice. All data is shown as mean ± SEM. Scale bar = 500 μm Image collected & cropped by CiteAb from the following publication (//bmcanesthesiol.biomedcentral.com/articles/10.1186/s12871-018-0509-5), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-13075_mouse-monoclonal-beta-amyloid-antibody-moab-2-310202416114798.jpg)
![N/A VEGFR1/Flt-1 [HRP]](http://images.novusbio.com/fullsize2/DATA_VEGF_R1_DVR100_ELISA_877.jpg "N/A VEGFR1/Flt-1 [HRP]")
![N/A VEGFR1/Flt-1 [HRP]](http://images.novusbio.com/fullsize2/VEGF_R1_DVR100_ELISA_2668.jpg)
![N/A VEGFR1/Flt-1 [HRP]](http://images.novusbio.com/fullsize2/VEGF_R1_DVR100_ELISA_2669.jpg)
![N/A VEGFR1/Flt-1 [HRP]](http://images.novusbio.com/fullsize2/VEGF_R1_DVR100_ELISA_397.jpg)
![N/A VEGFR1/Flt-1 [HRP]](http://images.novusbio.com/fullsize2/VEGF_R1_DVR100_ELISA_2670.jpg)
![N/A VEGFR1/Flt-1 [HRP]](http://images.novusbio.com/fullsize2/VEGF_R1_DVR100_ELISA_1180.jpg)
![N/A VEGFR1/Flt-1 [HRP]](http://images.novusbio.com/fullsize2/VEGF_R1_DVR100_ELISA_1181.jpg)
![N/A IL-18/IL-1F4 [HRP]](http://images.novusbio.com/fullsize2/IL18_DL180_ELISA_1164.jpg "N/A IL-18/IL-1F4 [HRP]")
![N/A IL-18/IL-1F4 [HRP]](http://images.novusbio.com/fullsize2/IL18_DL180_ELISA_1165.jpg)
![N/A IL-18/IL-1F4 [HRP]](http://images.novusbio.com/fullsize2/IL18_DL180_ELISA_1166.jpg)
![N/A CCL5/RANTES [Biotin]](http://images.novusbio.com/fullsize2/DATA_CCL5_DY478_ELISA_2058.jpg "N/A CCL5/RANTES [Biotin]")
![N/A Endothelin-1 [HRP]](http://images.novusbio.com/fullsize2/DATA_Endothelin1_DET100_ELISA_663.jpg "N/A Endothelin-1 [HRP]")
![N/A Endothelin-1 [HRP]](http://images.novusbio.com/fullsize2/Endothelin-1_DET100_ELISA_89.jpg)
![N/A CXCL12/SDF-1 alpha [HRP]](http://images.novusbio.com/fullsize2/DATA_CXCL12_SDF1_alpha_MCX120_ELISA_962.jpg "N/A CXCL12/SDF-1 alpha [HRP]")
![N/A CXCL12/SDF-1 alpha [HRP]](http://images.novusbio.com/fullsize2/CXCL12_MCX120_ELISA_257.jpg)